News

The NIH anticipates spending $150 million over five years to renew its Pharmacogenetics Research Network.

Patients with a specific combination of polymorphisms in genes responsible for the production of C-reactive protein (CRP) and interleukin-6 (IL-6) suffered stroke at three times higher rate.

The patent application is being filed in conjunction with major research institutions in the Houston area, with Power3 having an exclusive license to commercialize the technology involved.

Ciphergen will provide its suite of proteomic solutions designed for biomarker discovery and development of assays, to analyze patients' tumor cyst fluid and blood samples collected at University of Kentucky Healthcare.

Scientists have announced that they are investigating a class of pharmaceuticals that may well improve memory function, including those with Alzheimer's disease, and address some of the underlying causes of memory loss rather than today's drugs that simply treat symptoms.